摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1'-propan-2-ylspiro[3H-chromene-2,4'-piperidine]-4-one

中文名称
——
中文别名
——
英文名称
1'-propan-2-ylspiro[3H-chromene-2,4'-piperidine]-4-one
英文别名
——
1'-propan-2-ylspiro[3H-chromene-2,4'-piperidine]-4-one化学式
CAS
——
化学式
C16H21NO2
mdl
——
分子量
259.34
InChiKey
PULPPGDFHMPPQZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    19
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.562
  • 拓扑面积:
    29.5
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF
    申请人:Burstein S. Ethan
    公开号:US20070213359A1
    公开(公告)日:2007-09-13
    Disclosed herein are compounds of Formula I as defined herein, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, that modulates the activity of a ghrelin receptor. Disclosed herein are also methods of treating diseases or conditions that comprise administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I.
    本文披露了一些公式I定义的化合物,或其药学上可接受的盐,酯,酰胺或前药,该化合物调节胃饥饿素受体的活性。本文还披露了治疗疾病或病症的方法,包括向需要的受试者施用公式I的化合物的治疗有效量。
  • NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS
    申请人:Edmondson Scott D.
    公开号:US20120157432A1
    公开(公告)日:2012-06-21
    The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.
    本发明提供公式(I)的化合物、其制药组合物以及使用该化合物治疗或预防通过激活β3-肾上腺素受体介导的疾病的方法。
  • MODULATIONS OF PROTEASE ACTIVATED RECEPTORS
    申请人:Fairlie David Paul
    公开号:US20130184226A1
    公开(公告)日:2013-07-18
    The present invention provides novel compounds of the Formula (1), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.
  • MODULATORS OF PROTEASE ACTIVATED RECEPTORS
    申请人:Fairlie David
    公开号:US20140315796A1
    公开(公告)日:2014-10-23
    The present invention provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for therapies such as metabolic syndrome, obesity, type II diabetes, fibrosis and cardiovascular diseases, whether they are used alone or in combination with other treatment modalities.
  • US8354403B2
    申请人:——
    公开号:US8354403B2
    公开(公告)日:2013-01-15
查看更多